Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved docetaxel in combination with carboplatin, trastuzumab (s/c), and pertuzumab (tch(s/c)p) therapy for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence in adult patients.

This is written in the approval document as:

Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.

Reimbursement

Hybrid

Pertuzumab - ODMS; Trastuzumab, Carboplatin, and Docetaxel - Hospital

Citation

DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6601/731_v2_TCHSCP.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2020-07-01	Health Service Executive	Indication approved for reimbursement.